Richards Jennifer M, Farrar Emily J, Kornreich Bruce G, Moїse N Sydney, Butcher Jonathan T
Department of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
J Vet Cardiol. 2012 Mar;14(1):47-58. doi: 10.1016/j.jvc.2012.01.002. Epub 2012 Feb 25.
In degenerative valve disease, the highly organized mitral valve leaflet matrix stratification is progressively destroyed and replaced with proteoglycan rich, mechanically inadequate tissue. This is driven by the actions of originally quiescent valve interstitial cells that become active contractile and migratory myofibroblasts. While treatment for myxomatous mitral valve disease in humans ranges from repair to total replacement, therapies in dogs focus on treating the consequences of the resulting mitral regurgitation. The fundamental gap in our understanding is how the resident valve cells respond to altered mechanical signals to drive tissue remodeling. Despite the pathological similarities and high clinical occurrence, surprisingly little mechanistic insight has been gleaned from the dog. This review presents what is known about mitral valve mechanobiology from clinical, in vivo, and in vitro data. There are a number of experimental strategies already available to pursue this significant opportunity, but success requires the collaboration between veterinary clinicians, scientists, and engineers.
在退行性瓣膜病中,高度有序的二尖瓣小叶基质分层逐渐遭到破坏,并被富含蛋白聚糖、机械性能不佳的组织所取代。这是由原本静止的瓣膜间质细胞的活动所驱动的,这些细胞会转变为活跃的收缩性和迁移性肌成纤维细胞。虽然人类黏液瘤样二尖瓣疾病的治疗方法包括修复至完全置换,但犬类的治疗重点在于治疗由此产生的二尖瓣反流的后果。我们在理解上的根本差距在于,驻留的瓣膜细胞如何对改变的机械信号作出反应以驱动组织重塑。尽管存在病理相似性且临床发病率很高,但令人惊讶的是,从犬类研究中获得的机制性见解很少。本综述介绍了从临床、体内和体外数据中了解到的二尖瓣机械生物学知识。已经有许多实验策略可用于抓住这一重要机遇,但成功需要兽医临床医生、科学家和工程师之间的合作。